---

A concise review on analytical profile of naproxen

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Pritam’s Jain*

Volume : 4, Issue : 3, Year : 2019

Article Page : 70-81

https://doi.org/10.18231/j.ijcaap.2019.016

Suggest article by email

Get Permission

Abstract

Naproxen (NAP) is a Non-steroidal anti-inflammatory drugs (NSAID) used in the treatment of pain or inflammation caused by situations such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. Nap is available in isolated dosage from with various similar anti- inflammatory drugs, esomeprazole, pantoprazole, paracetamol, ranitidine, sumatriptan and ibuprofen. The present exploration evaluates the various method for analysing of NAP in bulk drugs and formulated products. A summarizing review characterizes the gathering and conversation of about more than 62 analytical methods which includes HPLC, HPTLC, UV-Spectrophotometry, capillary electrophoresis, electrochemical methods. HPLC technique are provided in Table03 and Table 04 for NAP alone and combination, including parameters such as matrix, stationary phase, mobile phase, wavelength detection etc. and HPTLC methods are reported in Table 05 with parameters like stationary phase, mobile phase combination, R_F etc. Method of UV-Spectrophotometry applied for examination of NAP in biological mediums, bulk sample and in various dosage formulation. Spectrometric methods for NAP alone and in mixture are given in Table 08 which includes parameters like ? max, solvent, matrix etc.

Keywords: Naproxen, HPLC, HPTLC, UV-Spectrophotometric, LC-MS/MS.

How to cite : Jain P, A concise review on analytical profile of naproxen. IP Int J Compr Adv Pharmacol 2019;4(3):70-81

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.